Related Experiment Videos
Management of malignant ventricular arrhythmias and cardiac arrest
1Indiana Heart Institute, Indianapolis, USA.
Insights
Sudden cardiac death is a major health issue. Implantable cardioverter defibrillators and amiodarone show promise in preventing cardiac arrest and improving survival rates in at-risk patients.
Area of Science:
- Cardiology
- Preventive Medicine
- Medical Devices
Background:
- Sudden cardiac death (SCD) remains a significant public health concern in the US, causing around 400,000 deaths annually.
- Recent advancements have focused on primary and secondary prevention strategies for SCD.
- Identifying at-risk individuals is crucial for effective intervention.
Purpose of the Study:
- To review recent advances in the prevention of sudden cardiac death.
- To highlight the role of implantable cardioverter defibrillators (ICDs) and amiodarone in managing cardiac arrhythmias.
- To discuss risk stratification methods for identifying patients at high risk of SCD.
Main Methods:
- Review of key clinical trials, including AVID, MADIT, and MUSTT.
- Analysis of therapeutic strategies for survivors of cardiac arrest and patients with recurrent ventricular arrhythmias.
- Examination of risk stratification tools for predicting SCD.
Main Results:
- The AVID study demonstrated the superiority of ICDs over amiodarone in survivors of cardiac arrest.
- Intravenous amiodarone is effective for recurrent ventricular tachycardia/fibrillation when other drugs fail.
- MADIT and MUSTT studies indicate improved survival with ICDs in specific patient groups (CAD, low ejection fraction, inducible VT).
Conclusions:
- Implantable cardioverter defibrillators are highly effective in preventing SCD in selected high-risk patients.
- Amiodarone remains a valuable therapeutic option for managing life-threatening ventricular arrhythmias.
- Risk stratification using electrophysiology testing aids in guiding ICD implantation decisions for improved patient outcomes.
Abstract:
Sudden cardiac death continues to be a major health problem in the United States, accounting for approximately 400,000 deaths per year. The last 10 yrs have seen major advances in the primary and secondary prevention of this problem. In patients who have survived an episode of cardiac arrest, the AVID study conclusively established the superiority of the implantable cardioverter defibrillator over empiric amiodarone. For patients with recurrent hemodynamically destabilizing ventricular tachycardia and ventricular fibrillation, intravenous amiodarone has emerged as a potent therapeutic agent, especially when other agents such as lidocaine and procainamide have not been effective. Finally, recent work has focused on the risk stratification of patients for sudden cardiac death. Both the MADIT and MUSTT studies suggest that patients with coronary artery disease, reduced ejection fraction, and nonsustained ventricular tachycardia who are inducible to a sustained ventricular arrhythmia at electrophysiology testing have improved survival with an implantable cardioverter defibrillator.